ReviewBMB reports2020
Non-classical role of Galectin-3 in cancer progression: translocation to nucleus by carbohydrate-recognition independent manner.
Review in BMB reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 33 citations in OpenAlex.
- Molecular regulation of estrogen receptors and recent advances on ERα36 splice variant in prostate cancer.Journal of the Endocrine Society · 2026Article
- Expression, Localization and Actions of Galectin-3: Implications in the Pathophysiology and Therapy of Cardiovascular Disease.International journal of molecular sciences · 2026Review
- Galectin-3-A Multifunctional Molecule and a Key Player in Health and Disease.Molecules (Basel, Switzerland) · 2026Review
- Galectins at the crossroads of tumor immunity, metabolism, and metastasis: mechanisms, therapeutic resistance, and translational opportunities.Frontiers in immunology · 2026Review
- Integration of single-cell and bulk RNA sequencing data to identify liquid-liquid phase separation-related prognostic biomarkers in hepatocellular carcinoma.Scientific reports · 2025Article
- The Predictive Significance of Galectin 3 Expression in Patients with Unresectable Non-Small Cell Lung Cancer without EGFR or ALK Mutations Treated Platinum-Based Doublet Chemotherapy.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Multifaceted roles of Galectins: from carbohydrate binding to targeted cancer therapy.Biomarker research · 2025Review
- Characteristic abnormal expression of galectin-3 in serrated colon lesions and its pathological significance.Histology and histopathology · 2025Article
- Early Cardiac Ischemia-Reperfusion Injury: Interactions of Autophagy with Galectin-3 and Oxidative Stress.Biomedicines · 2024Article
- Novel strategies in Parkinson's disease treatment: a review.Frontiers in molecular neuroscience · 2024Review
- Bcl-2 and galectin-3 expression is associated with recurrence of ameloblastoma.Dental research journal · 2024Article
- Article
- Anti(angiogenic) food components: can be a major source of bias in the investigation of angiogenesis inhibitors.Annals of translational medicine · 2023Review
- Periplocin suppresses the growth of colorectal cancer cells by triggering LGALS3 (galectin 3)-mediated lysophagy.Autophagy · 2023Article
- Galectin-3's Complex Interactions in Pancreatic Ductal Adenocarcinoma: From Cellular Signaling to Therapeutic Potential.Biomolecules · 2023Review
- Tree of life: endothelial cell in norm and disease, the good guy is a partner in crime!Anatomy & cell biology · 2023Review
- Galectin-3 promotes secretion of proteases that decrease epithelium integrity in human colon cancer cells.Cell death & disease · 2023Article
- The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma.Advances in cancer research · 2023Review
- Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor.Frontiers in endocrinology · 2023Review
- Chronic kidney disease predictors in obese adolescents.Pediatric nephrology (Berlin, Germany) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Galectin-3 is a carbohydrate-binding protein and regulates diverse functions, including cell proliferation and differentiation, mRNA splicing, apoptosis induction, immune surveillance and inflammation, cell adhesion, angiogenesis, and cancer-cell metastasis. Galectin-3 is also recommended as a diagnostic or prognostic biomarker of various diseases, including heart disease, kidney disease, and cancer. Galectin-3 exists as a cytosol, is secreted in extracellular spaces on cells, and is also detected in nuclei. It has been found that galectin-3 has different functions in cellular localization: (i) Extracellular galectin-3 mediates cell attachment and detachment. (ii) cytosolic galectin-3 regulates cell survival by blocking the intrinsic apoptotic pathway, and (iii) nuclear galectin-3 supports the ability of the transcriptional factor for target gene expression. In this review, we focused on the role of galectin-3 on translocation from cytosol to nucleus, because it happens in a way independent of carbohydrate recognition and accelerates cancer progression. We also suggested here that intracellular galecin-3 could be a potent therapeutic target in cancer therapy. [BMB Reports 2020; 53(4): 173-180].
Indexed as
Identifiers
32172730PMC7196190W3011508566What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.